Axsome and Sanofi face FDA verdicts in depression and Pompe disease respectively, while a Keytruda combo ups the ante in kidney cancer.
Late-stage data are expected for Apellis; Ionis and Biogen tackle ALS; and Mirati awaits combination results.
Biogen’s Aduhelm was the big one, but there are plenty of other key regulatory decisions still pending this year.
Blockbuster sales are predicted for several projects nearing approval, from Biogen, Argenx, Fibrogen and others.
Trial results in Covid-19 and cancer emerge, but little promise is seen.
Investors are piling into biotech IPOs, but the track record of previous years' new issues shows how hard it is to pick winners.
Coronavirus aside, biotech companies including Akebia, Blueprint, Genfit and TG Therapeutics are set for some important data readouts in the next couple of months.